Arcutis Biotherapeutics
Arcutis Biotherapeutics specializes in developing treatments for inflammatory dermatological conditions, with FDA-approved products like ZORYVE for seborrheic dermatitis and psoriasis, and a focus on inclusive clinical trials.
FDA Approvals
Arcutis Biotherapeutics has received two distinct FDA approvals for its product, ZORYVE (roflumilast). One approval is for ZORYVE topical foam, 0.3%, targeted at treating Seborrheic Dermatitis in individuals aged 9 years and older. The other approval is for ZORYVE Cream 0.3%, intended for treating Psoriasis in children aged 6 to 11. These FDA approvals underline the company's capability in developing effective treatments for various dermatological conditions.
Patient Assistance Program
Arcutis Biotherapeutics offers a patient assistance program (PAP) that provides ZORYVE foam at no cost to eligible uninsured or underinsured patients who demonstrate financial need. This program is designed to make their treatments more accessible to a wider range of patients, ensuring that those in financial need can benefit from their FDA-approved dermatological therapies.
Pipeline and Research Development
Arcutis Biotherapeutics has a robust pipeline that includes multiple clinical programs evaluating innovative therapeutics such as PDE4, JAK1, and CD200R agonists. These programs focus on a range of inflammatory dermatological conditions, reflecting the company's commitment to developing advanced treatments. Their research incorporates the development of proprietary topical formulations that are optimized to deliver medication effectively into the skin.
Diversity in Clinical Trials
Arcutis Biotherapeutics is committed to the principle of diversity and inclusion in its clinical trials. They make substantial efforts to ensure that their trials have adequately diverse populations. This approach not only helps in understanding the efficacy of treatments across different demographics but also promotes inclusivity in medical research.